Two board members have been reappointed for two years, while three others have had their term extended by a year.
Similar Posts
Device specific vigilance guidance: Artificial Heart Valves
Guidance for manufacturers of artificial heart valves. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Form: Blood bank compliance report template
Template for a blood bank compliance report and guidance on completing it.
Guidance: MORE implementation
Guidance on the updates to reporting forms following implementation of the Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024.
MHRA approves sebetralstat (Ekterly) to treat hereditary angioedema (HAE) attacks in patients aged 12 and over
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older.
Patients to benefit as UK and US regulators forge new collaboration on medical technologies and AI
Enhanced collaboration with the US on med tech regulation, with accelerated innovation, strengthened patient safety, and reduced transatlantic barriers to market access.
Guidance: Risk minimisation measures for medicines
Guidance for healthcare professionals on risk minimisation options for medicines.